Cargando…

P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS

Detalles Bibliográficos
Autores principales:	Hu, Lijuan, Zhao, Wei-LI, Wu, Wen, Wei, Xudong, MI, Ruihua, Hu, Yu, LI, Qiubai, He, Wenjuan, LI, Juan, Dong, Yugang, Wang, Hehua, Zhang, Xuhan, Zhang, Yu, Xu, Zhongyuan, Liu, Hui, Cai, Zhen, Sun, Jie, Xu, Yajing, Jiang, Zhiping, Zhang, Cheng, Chen, Guo, Gong, Tiejun, Tang, Qinghua, Jing, Hongmei, MA, Lan, Gao, Sujun, Liu, Qiqi, Zhong, Zeyu, Ren, Yongxin, Chen, Jian, Fan, Songhua, Shi, Michael, Su, Weiguo, Huang, Xiaojun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429314/ http://dx.doi.org/10.1097/01.HS9.0000969064.86312.d3

Ejemplares similares

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP(+)-dependent isocitrate dehydrogenase (IDH)
por: Yang, Jinsung, et al.
Publicado: (2017)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells
por: Shait Mohammed, Mohammed Razeeth, et al.
Publicado: (2022)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City
por: Olarte, Irma, et al.
Publicado: (2019)

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
por: Chotirat, Sadudee, et al.
Publicado: (2012)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

Glioma immunotherapy enhancement and CD8-specific sialic acid cleavage by isocitrate dehydrogenase (IDH)-1
por: Cordner, Ryan, et al.
Publicado: (2023)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma
por: Lang, Fengchao, et al.
Publicado: (2021)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Exploiting Electrode Nanoconfinement to Investigate the Catalytic Properties of Isocitrate Dehydrogenase (IDH1) and a Cancer-Associated Variant
por: Herold, Ryan A., et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas
por: Amary, M. Fernanda, et al.
Publicado: (2014)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning
por: Liu, Sidong, et al.
Publicado: (2020)

Crystal Structure of the Isocitrate Dehydrogenase 2 from Acinetobacter baumannii (AbIDH2) Reveals a Novel Dimeric Structure with Two Monomeric-IDH-Like Subunits
por: Wang, Peng, et al.
Publicado: (2018)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status
por: Tabei, Yusuke, et al.
Publicado: (2020)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

The Long Non-Coding RNA IDH1-AS1 Promotes Prostate Cancer Progression by Enhancing IDH1 Enzyme Activity
por: Wu, Shuo, et al.
Publicado: (2020)

Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma
por: van Lith, Sanne A. M., et al.
Publicado: (2016)

Mutation Analysis of IDH1 in Paired Gliomas Revealed IDH1 Mutation Was Not Associated with Malignant Progression but Predicted Longer Survival
por: Yao, Yu, et al.
Publicado: (2013)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α via IDH1 to regulate the Warburg effect
por: Xiang, Shaoxun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0rnh85qgse28gimm3nojcjc24l